Press Releases :: IceCure Medical Ltd. (ICCM)

Skip to main content Skip to section navigation Skip to footer

Dec 23, 2022 4:00 pm EST

IceCure Medical Ltd. Announces Closing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Dec 21, 2022 9:00 am EST

IceCure Medical Ltd. Announces Pricing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Dec 20, 2022 4:00 pm EST

IceCure Medical Ltd. Announces Proposed Public Offering

Dec 19, 2022 4:05 pm EST

IceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results

Dec 06, 2022 8:00 am EST

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

Dec 05, 2022 7:00 am EST

IceCure Medical Reports Financial Results for the Nine Months Ended September 30, 2022 and Provides Update on Recent Operational Highlights

Nov 30, 2022 8:00 am EST

IceCure's ProSense Featured in Poster Presentation at Radiological Society of North America's 2022 Annual Meeting

Nov 29, 2022 8:00 am EST

TIME CHANGE: IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022

Nov 28, 2022 8:00 am EST

IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022

Nov 08, 2022 8:00 am EST

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

Select a page:

rss_feed News RSS

IceCure Medical HQ: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel

© 2025 All Rights Reserved IceCure Medical

Branding by

Terms of Use | Privacy | Last Updated: April 9, 2023